Hims & Hers Health: Navigating Legal Storms and Reinventing Resilience in the GLP-1 Wars

The weight-loss drug market, now a $30 billion battleground, is witnessing unprecedented upheaval as regulatory scrutiny and patent battles redefine industry boundaries. At the epicenter stands Hims & Hers Health, a telehealth pioneer now grappling with existential legal threats from Novo Nordisk and the FDA. Yet, the company's pivot to personalized compounding and non-GLP-1 revenue streams offers a glimmer of hope. Is Hims & Hers a survivor or a casualty of the GLP-1 gold rush? Let's dissect the risks and resilience.

---

### The Legal Headwinds: A Threat to Core Revenue?
Novo Nordisk's June 2025 termination of its partnership with Hims & Hers—and the subsequent lawsuits—mark a turning point. The FDA's resolution of the Wegovy shortage in April 2025 eliminated the “emergency” justification for compounded semaglutide sales, while federal courts have upheld enforcement actions against pharmacies producing knockoff versions. Hims, which derived ~$280 million of its 2024 revenue from compounded GLP-1 drugs, now faces a stark choice: abandon these products or risk fines and reputational damage.

The stakes are high.

Legal actions have already triggered a 20% stock selloff, but the broader concern is whether Hims can replace lost semaglutide revenue. Novo's push to restrict compounded versions—arguably cheaper alternatives to branded drugs—threatens not only Hims' margins but also its telehealth partnerships, which relied on easy access to these treatments.

---

### Pivoting to Stay Afloat: Diversification or Distraction?
Hims' response has been swift. The company is leaning into two strategies:
1. Personalized Compounding for Clinical Necessity: Shifting focus to niche cases requiring customized dosing (e.g., pediatric use), which FDA rules still permit under 503A exemptions.
2. Non-GLP-1 Growth: Leveraging its $1.2 billion non-GLP-1 revenue base (81% of 2024 total) in mental health, dermatology, and sexual wellness. Projections for 2025 aim for $2.3–2.4 billion in total revenue, with $725 million from weight-loss offerings excluding semaglutide.

Critical to this pivot are acquisitions like Trybe Labs (at-home lab testing) and a California peptide facility, which expand its ability to offer data-driven, personalized treatments. The company's subscription model (90% of revenue) also provides stability, with 2.2 million subscribers as of 2024.



While Hims' stock has underperformed Novo's over the past year, its 2025 guidance relies on operational leverage: adjusted EBITDA is projected to hit $270–320 million, up from $190 million in 2024. This suggests cost controls and vertical integration (e.g., its MedisourceRx pharmacy) are paying dividends.

---

### Wall Street's Mixed Verdict: Growth or Gambles?
Analysts are divided. Truist recently raised its price target to $14, citing Hims' “strategic agility” and the potential for liraglutide (a cheaper generic GLP-1) to fill the semaglutide void. Conversely, firms like Morgan Stanley remain skeptical, arguing that litigation risks and insurer pushback on obesity coverage could cap growth.

The disconnect hinges on two factors:
- Near-Term Risks: Ongoing lawsuits and FDA enforcement could divert capital from growth initiatives.
- Long-Term Potential: If Hims can solidify its telehealth platform and leverage personalized care, it could carve out a niche in a market expected to hit $50 billion by 2030.

---

### Broader Market Dynamics: A Battle for Access and Profit Margins
The GLP-1 wars are not just about patents—they're about pricing power. The Trump administration's May 2025 executive order aims to slash drug costs by 59–90%, pressuring Big Pharma to lower prices. Novo's temporary $199/month Wegovy discount and Eli Lilly's $349–$499 Zepbound tiers reflect this pressure.

For Hims, the shift opens opportunities:
- Generic Liraglutide: By offering a $350/month alternative, Hims can attract price-sensitive patients without relying on compounded drugs.
- Telehealth as a Differentiator: Its vertically integrated platform—combining consultations, diagnostics, and pharmacy—gives it an edge over rivals lacking such infrastructure.

However, insurers like CVS Caremark's exclusion of Zepbound (despite clinical efficacy) underscores the risk of coverage fragmentation. Hims must navigate these complexities to ensure its services remain accessible.

---

### Conclusion: A Risky Gamble with a Silver Lining
Hims & Hers is at a crossroads. The legal and regulatory challenges are severe, with compounded semaglutide sales now a liability. Yet, its diversified revenue streams, subscription model, and strategic acquisitions position it to weather the storm—if it can execute flawlessly.

Investors should weigh two scenarios:
1. Best Case: Hims successfully transitions to FDA-approved generics and personalized care, leveraging its telehealth scale to achieve EBITDA margins above 15%. This could justify a stock price recovery.
2. Worst Case: Prolonged litigation, insurer pushback, and margin pressures force a retreat to core services, limiting upside.

For now, the stock's valuation (P/S ratio of ~1.5x) reflects this uncertainty. Aggressive investors may see value in a “turnaround” play, but cautious players should wait for clearer visibility on litigation outcomes and revenue diversification success.

In the $30 billion weight-loss market, adaptability is key—and Hims, for all its risks, is proving more agile than many assume.

---
Investment advice: Consider Hims & Hers as a speculative play for investors with a high risk tolerance, but prioritize monitoring FDA litigation updates and EBITDA margin trends before committing capital.